201 related articles for article (PubMed ID: 37923671)
41. A Rapid and Specific HPLC Method to Determine Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Scarlattei M; Baldari G; Silva C; Ruffini L
Curr Radiopharm; 2021; 14(2):121-130. PubMed ID: 32990551
[TBL] [Abstract][Full Text] [Related]
42. A comparison of the performance of
Yin X; Ai K; Luo J; Liu W; Ma X; Zhou L; Xiang X; Su X; Wang Y; Li Y
Front Endocrinol (Lausanne); 2024; 15():1291775. PubMed ID: 38419957
[TBL] [Abstract][Full Text] [Related]
43. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.
Vag T; Gerngross C; Herhaus P; Eiber M; Philipp-Abbrederis K; Graner FP; Ettl J; Keller U; Wester HJ; Schwaiger M
J Nucl Med; 2016 May; 57(5):741-6. PubMed ID: 26769866
[TBL] [Abstract][Full Text] [Related]
44. Chemokine receptor - Directed imaging and therapy.
Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
[TBL] [Abstract][Full Text] [Related]
45. Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [
Derlin T; Sedding DG; Dutzmann J; Haghikia A; König T; Napp LC; Schütze C; Owsianski-Hille N; Wester HJ; Kropf S; Thackeray JT; Bankstahl JP; Geworski L; Ross TL; Bauersachs J; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1934-1944. PubMed ID: 29967943
[TBL] [Abstract][Full Text] [Related]
46. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.
Wester HJ; Keller U; Schottelius M; Beer A; Philipp-Abbrederis K; Hoffmann F; Šimeček J; Gerngross C; Lassmann M; Herrmann K; Pellegata N; Rudelius M; Kessler H; Schwaiger M
Theranostics; 2015; 5(6):618-30. PubMed ID: 25825601
[TBL] [Abstract][Full Text] [Related]
47. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
48. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
49. Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on
Xu L; Tetteh G; Lipkova J; Zhao Y; Li H; Christ P; Piraud M; Buck A; Shi K; Menze BH
Contrast Media Mol Imaging; 2018; 2018():2391925. PubMed ID: 29531504
[TBL] [Abstract][Full Text] [Related]
50. Chemokine receptor-4 targeted PET/CT with
Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
[TBL] [Abstract][Full Text] [Related]
51. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results.
Mayerhoefer ME; Jaeger U; Staber P; Raderer M; Wadsak W; Pfaff S; Kornauth C; Senn D; Weber M; Wester HJ; Skrabs C; Haug A
Invest Radiol; 2018 Jul; 53(7):403-408. PubMed ID: 29642081
[TBL] [Abstract][Full Text] [Related]
52. CXCR4-targeted theranostics in oncology.
Buck AK; Serfling SE; Lindner T; Hänscheid H; Schirbel A; Hahner S; Fassnacht M; Einsele H; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4133-4144. PubMed ID: 35674738
[TBL] [Abstract][Full Text] [Related]
53. Imaging of Chemokine Receptor CXCR4 in Mycosis Fungoides Using 68Ga-Pentixafor PET/CT.
Kuyumcu S; Yilmaz E; Büyükkaya F; Özkan ZG; Ünal SN
Clin Nucl Med; 2018 Aug; 43(8):606-608. PubMed ID: 29916918
[TBL] [Abstract][Full Text] [Related]
54. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
55.
Kraus S; Dierks A; Rasche L; Kertels O; Kircher M; Schirbel A; Zovko J; Steinbrunn T; Tibes R; Wester HJ; Buck AK; Einsele H; Kortüm KM; Rosenwald A; Lapa C
J Nucl Med; 2022 Jan; 63(1):96-99. PubMed ID: 34049979
[TBL] [Abstract][Full Text] [Related]
56. CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
Hartlapp I; Hartrampf PE; Serfling SE; Wild V; Weich A; Rasche L; Roth S; Rosenwald A; Mihatsch PW; Hendricks A; Wiegering A; Wiegering V; Hänscheid H; Schirbel A; Werner RA; Buck AK; Wester HJ; Einsele H; Kunzmann V; Lapa C; Kortüm KM
J Nucl Med; 2023 Sep; 64(9):1424-1430. PubMed ID: 37348915
[TBL] [Abstract][Full Text] [Related]
57. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y; Long T; Peng N; Zhen M; Ye Q; Zhang Z; He Y; Chen Z; Gan Y; Luo M; Li C; Liu Z; Guo M; Wang M; Luo X; Hu S; Liu L; Jiang T
J Clin Endocrinol Metab; 2023 Dec; 109(1):171-182. PubMed ID: 37477496
[TBL] [Abstract][Full Text] [Related]
58. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract][Full Text] [Related]
59. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using
Ding J; Tong A; Zhang Y; Wen J; Zhang H; Hacker M; Huo L; Li X
J Nucl Med; 2022 Mar; 63(3):368-375. PubMed ID: 34301781
[TBL] [Abstract][Full Text] [Related]
60. CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma.
Herhaus P; Lipkova J; Lammer F; Yakushev I; Vag T; Slotta-Huspenina J; Habringer S; Lapa C; Pukrop T; Hellwig D; Wiestler B; Buck AK; Deckert M; Wester HJ; Bassermann F; Schwaiger M; Weber W; Menze B; Keller U
J Nucl Med; 2020 Dec; 61(12):1765-1771. PubMed ID: 32332145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]